Avelumab

BNF:
Not listed
Status:
Red
Decision Date:
May 2018
 

Comments

RED:

  • NICE TA517: for treating metastatic Merkel Cell carcinoma.  (Decision date - May 2018).
  • NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma.  (Decision date - Oct 2020). 
  • NICE TA691: for untreated metastatic Merkel cell carcinoma.  (Decision date - May 2021). 
  • NICE TA788: for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy.  (Decision date - June 2022).

 Available through the Cancer Drug Fund.

NHS England drug.  To be used in line with NHSE commissioning intentions.

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
  • 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
  • 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app